Effect of bariatric surgery on adiposity and metabolic profiles: A prospective cohort study in Middle-Eastern patients

Table 1 Changes of anthropometrical and clinical factors from baseline to 12 mo follow up

Factors	Baseline (91)	3 mo (86)	6 mo (83)	12 mo (80)	P value
BMI (kg/m2)	41.9 ± 4.5	37.1 ± 5.0	34.0 ± 4.6	29.5 ± 3.8	< 0.001
FM	64.2 ± 11.4	50.7 ± 9.2	40.1 ± 8.7	34.7 ± 8.2	< 0.001
FFM	68.3 ± 15.2	64.1 ± 15.8	60.7 ± 16.3	58.0 ± 16.6	< 0.001
LDL (mg/dL)	162.2 ± 9.7	147.9 ± 11.3	139.7 ± 13.2	122.8 ± 19.5	< 0.001
HDL (mg/dL)	35.7 ± 3.0	37.1 ± 3.4	36.9 ± 3.7	39.4 ± 5.3	< 0.001
TG (mg/dL)	232.6 ± 26.1	208.5 ± 31.3	168.2 ± 28.7	132.6 ± 25.8	< 0.001
TC (mg/dL)	244.1 ± 20.1	224.9 ± 24.8	198.2 ± 28.4	180.2 ± 42.7	< 0.001
FBG (mg/dL)	142.5 ± 18.1	115.1 ± 15.8	102.5 ± 10.1	97.1 ± 8.2	< 0.001
HbA1c (%)	6.8 ± 1.1	5.7 ± 0.92	5.5 ± 1.0	5.4 ± 1.2	< 0.001
ALT (IU/L)	44.8 ± 8.5	33.0 ± 9.6	30.1 ± 9.4	25.1 ± 8.3	< 0.001
AST (IU/L)	35.7 ± 7.0	28.1 ± 5.5	24.5 ± 5.2	23.5 ± 4.8	< 0.001
Total Bilirubin (mg/dL)	5.0 (3.2-6.1)	6.0 (4.1-8.5)	8.0 (5.5-9.5)	9.0 (6.1-11.8)	< 0.001
Hs-CRP (mg/dL)	24.0 (19.0-26.0)	20.0 (14.5-27.2)	18.1 (12.1-26.6)	7.7 (4.6-10.8)	< 0.001

Values expressed as mean ± SD for normally distributed data, and median and 25^th-75^th percentiles for non-normally distributed data. P-value is from the ANOVA or Kruskal-Wallis and it refers to total difference between follow up times. BMI: Body mass index; FBG: Fasting blood glucose; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TG: Triglyceride; TC: Total cholesterol; ALT: Alanine transaminase; AST: Aspartate transaminase; Hs-CRP: High-sensitivity C-reactive protein; FM: Fat mass; FFM: Fat free mass.